|
|
Article: New Data Shows Patients Taking Pfizer's Norvasc Achieved Superior Blood Pressure Control With Fewer Heart Attacks.
- Article from:
- PR Newswire
- Article date:
- June 14, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
PARIS, June 14 /PRNewswire/ -- Patients taking Pfizer's blood pressure-lowering medicine Norvasc (amlodipine besylate) achieved superior blood pressure control and had significantly fewer heart attacks, according to findings from a major new clinical trial presented at the annual meeting of the European Society of Hypertension.
The four-year, 15, 245-patient trial compared the calcium channel blocker Norvasc with the angiotensin-receptor blocker valsartan. Norvasc patients reached lower blood pressure levels earlier, and maintained better blood pressure control throughout the trial compared with valsartan patients. In addition, Norvasc patients were treated ...